Abstract
Clinical application of the oral administration of phenoxybenzamine has been investigated in 41 patients with benign prostatic hypertrophy and 5 patients with bladder neck contracture. Residual amount of urine was reduced in 46% of cases after the treatment. The change in length of continence zone and the value of maximum urethral pressure, which were measured with urethral pressure profile, was not statistically significant comparing to the values prior to the treatment. The improvement of uroflowmetrogram and subjective symptom was observed in 76% and 91% of cases, respectively. The effective maintenance dose was found 7.5 to 15mg per day. Adverse effects were noted in 26% of cases. 39 cases were successfully treated with phenoxybenzamine, while 3 were not. The remaining 4 had to be changed to other medication due to the adverse effects.Phenoxybenzamine does not shrink the prostatic adenoma per se, but functionally reduces the urethral resistance and alleviates the obstructive symptoms present in the lower urinary tract. Phenoxybenzamine was found quite of promise to achieve a satisfactory voiding in patients suffering from benign prostatic hypertrophy and bladder neck contracture also.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
